Factors affecting renal involvement in immunoglobulin A vasculitis

Year 2023, Volume: 28 Issue: 2, 176 - 185, 23.05.2023

Nimet Öner Serkan Coşkun Tuba Kurt Vildan Güngörer Elif Çelikel Zahide Ekici Tekin Nilüfer Tekgöz Müge Sezer Cüneyt Karagöl Melike Mehveş Kaplan Merve Cansu Polat Özlem Yüksel Aksoy Umut Selda Bayrakçı Banu Acar

https://doi.org/10.21673/anadoluklin.1221278

Abstract

Aim: The aim of this study was to evaluate the factors affecting the duration of renal involvement in children with immunoglobulin A vasculitis (IgAV; formerly Henoch Schonlein Purpura).

Methods: Data from IgAV patients who were followed up on for at least a year between January 2015 and June 2022 were analyzed retrospectively. Demographic, clinical, laboratory findings and treatments were recorded.

Results: The study included 372 IgAV patients, 81 of whom had IgAV kidney involvement. Forty-six (56.8%) of the patients were male and 35 (43.2%) were female. All patients had skin involvement, 32 (39.5%) had joint involvement, 44 (54.3%) had gastrointestinal (GI) tract involvement, and 2 (2.5%) had neurologic involvement. 3 patients had hypertension at the time of diagnosis. Renal involvement was diagnosed at the time of diagnosis in 45 patients (55.5%), within the first 2 weeks in 10 patients (12.4%), between weeks 2-4 in 12 patients (14.8%), and between 1 month and 3 months in 14 patients (17.3%). After 3 months, there was no renal involvement. Renal involvement at the time of diagnosis was associated with older age and low albumin level, and renal involvement at 1-3 months was associated with joint and GI tract involvement. Among patients with renal involvement, those with renal involvement and nephrotic proteinuria at diagnosis had longer time to recovery. Patients with renal involvement and hematuria between 1-3 months had a shorter time to recovery.

Conclusion: The development of IgAV-renal involvement in older age and those with low albumin levels should be carefully monitored. Especially the first 3 months is a risky period in terms of development of renal involvement.

Keywords

Child, immunoglobulin A, proteinuria

İmmünoglobulin A vaskülitinde böbrek tutulumunu etkileyen faktörler

Abstract

Amaç: Bu çalışmada immünglobulin A vasküliti İmmünoglobulin A vasküliti (IgAV; eski adıyla Henoch Schonlein Purpurası) olan çocuklarda böbrek tutulumunun zamanını etkileyen faktörlerin ortaya konulması amaçlanmıştır.

Yöntemler: Ocak 2015- Haziran 2022 arasında IgAV tanısı ile en az 1 yıl takip edilen hastaların verileri geriye dönük olarak incelendi. Hastaların demografik, klinik, laboratuar verileri ve uygulanan tedaviler kaydedildi.

Bulgular: Çalışmaya 372 IgAV hastası dahil edildi, bu hastaların 81’inde IgAV böbrek tutulumu vardı. Hastaların 46’sı (%56,8) erkek, 35’i (%43,2) kızdı. Hastaların tamamında cilt tutulumu, 32’sinde (%39,5) eklem, 44’ünde (%54,3) gastrointestinal sistem (GİS), 2’sinde (%2,5) nörolojik tutulum vardı. 3 hastada tanı anında hipertansiyon vardı. Böbrek tutulumu, 45 hastada (%55,5) tanı anında, 10 hastada (%12,4) ilk 2 hafta içinde, 12 hastada (%14,8) 2-4. haftalar arasında, 14 hastada (%17,3) 1 ay-3 ay arasında saptandı. 3 aydan sonra böbrek tutulumu olmadı. Tanı anında böbrek tutulumu ile tanı yaşının büyük ve albümin düzeyinin düşük olması; 1-3 ayda böbrek tutulumu gelişmesi ile eklem ve GİS tutulumu arasında ilişki bulundu. Böbrek tutulumu olan hastalar içinde iyileşme süresi en uzun olanlar, tanı anında böbrek tutulumu saptananlar ve nefrotik düzeyde proteinüri olan hastalardı. İyileşme süresi en kısa olanlar ise, 1-3 ay arası böbrek tutulumu olan ve hematüri saptananlardı.

Sonuç: Büyük yaştaki çocuklarda ve düşük albümin düzeyi olanlarda IgAV-böbrek tutulumunun gelişimi dikkatle takip edilmelidir. Özellikle ilk 3 ay böbrek tutulumunun saptanması için riskli dönemdir.

Keywords

Çocuk, immünglobulin A, proteinüri

References

• Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol. 2013;17(5):603–6.
• Chen J, Fang X, Dang X, et al. Association of the paired box 2 gene polymorphism with the susceptibility and pathogenesis of Henoch Schönlein purpura in children. Mol Med Rep. 2015;11(3):1997-2003.
• Yakut HI, Kurt T, Uncu N et al. Predictive role of neutrophil to lymphocyte ratio and mean platelet volume in Henoch-Schönlein purpura related gastrointestinal and renal involvement. Arch. Argent. Pediatr. 2020;118:139–42.
• Davin JC, Ten Berge IJ, Weening JJ. What is the difference between IgA nephropathy and Henoch-Schonlein purpura nephritis?. Kidney Int. 2001;59(3):823–34.
• Ozen S, Pistorio A, Iusan S, et al. Paediatric Rheumatology International Trials Organisation. EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69(5):798-806.
• Edström HS, Söderberg MP, Berg UB. Predictors of outcome in Henoch-Schönlein nephritis. Pediatr Nephrol. 2010;25:1101–8.
• Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.
• Kawasaki Y, Suyama K, Yugeta E, et al. The incidence and severity of Henoch- Schoenlein purpura nephritis over a 22- year period in Fukushima Prefecture, Japan. Int Urol Nephrol. 2010;42(4):1023-9.
• Yap K, Lau PYW. Hematuria and proteinuria. In: Pediatric Kidney Disease. Springer, Berlin, Heidelberg. 2016;p.391-418.
• Flynn JT, Kaelber DC, Baker-Smith CM, et al. Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics, 2017;140(3):e20171904.
• Mian AN, Schwartz GJ. Measurement and estimation of glomerular filtration rate in children. Adv Chronic Kidney Dis. 2017;24:348-56.
• Salvador CL, Tondel C, Rowe AD, et al. Estimating glomerular filtration rate in children: evaluation of creatinine- and cystatin C-based equations. Pediatr Nephrol. 2019;34:301-11.
• Barnett HL. International study of kidney disease in children. Nihon Jinzo Gakkai Shi. 1979;21(10):1141-4.
• Ozen S, Marks SD, Brogan P, et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis—the SHARE initiative. Rheumatology. 2019;58(9):1607-16.
• Rai A, Nast C, Adler S. Henoch-Schönlein purpura nephritis. J Am Soc Nephrol. 1999;10:2637-44.
• Coppo R, Mazzucco G, Cagnoli L, et al. Long-term prognosis of HenochSchönlein nephritis in adults and children. Italian Group of Renal Immunopathology Collaborative Study on Henoch-Schonlein purpura. Nephrol Dial Transplant.1997;12:2277–83.
• Narchi, H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schönlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child. 2005;90(9):916-20.
• Jauhola O, Ronkainen J, Koskimies O, et al. Renal manifestations of Henoch–Schönlein purpura in a 6-month prospective study of 223 children. Arch Dis Child. 2010;95(11):877-82.
• Carucci NS, La Barbera G, Peruzzi L, et al. Time of Onset and Risk Factors of Renal Involvement in Children with Henoch-Schönlein Purpura: Retrospective Study. Children 2022;9:1394.
• Davin JC, Coppo R. Henoch-Schönlein purpura nephritis in children. Nat Rev Nephrol. 2014;10(10):563-73.
• Pohl M. Henoch–Schönlein purpura nephritis. Pediatr Nephrol. 2015;30(2):245–52.
• Chan H, Tang YL, Lv XH, et al. Risk factors associated with renal involvement in childhood Henoch-Schönlein Purpura: a meta-analysis. PLoS One. 2016;11:e0167346.
• Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney international. 2021;100(4):753–79.